Covered recipient · General Payments record
DAVID HAKIMIAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,545.96
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,545.96 | 103 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID HAKIMIAN
NPI 1972590347 · CMS profile ID 179978
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NILES, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972590347?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972590347?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972590347?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1972590347?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $2,545.96 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–103 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $24.59 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228863553 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.48 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223919072 | CMS |
| Astellas Pharma US Inc | $34.98 | 01/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238728186 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $845,278.66 | 327 |
| PY2024 | Principal investigator | $575,151.40 | 117 |
| PY2023 | Principal investigator | $856,007.56 | 264 |
| PY2022 | Recipient | $3,900.00 | 7 |
| PY2022 | Principal investigator | $43,896.65 | 17 |
| PY2021 | Principal investigator | $90,252.10 | 23 |
| PY2020 | Principal investigator | $83,399.80 | 20 |
| PY2019 | Principal investigator | $117,535.70 | 28 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
327 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,000.00 | 12/31/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS NILES | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) | No dispute reported | 06/30/2026 | 1185554428 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387755 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 12/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 12/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369800 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 12/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228814247 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753366 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387753 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387757 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387759 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387763 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387767 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387769 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387771 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387773 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387775 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387777 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387779 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387781 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387783 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387785 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $588.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387787 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387789 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387791 |
| Principal investigator 1 | BioNTech SE | $92.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019572 |
| Principal investigator 1 | BioNTech SE | $245.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019574 |
| Principal investigator 1 | BioNTech SE | $92.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019578 |
| Principal investigator 1 | Amgen Inc. | $34,000.00 | 11/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTION LLC | A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 | No dispute reported | 06/30/2026 | 1246647989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,000.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326792 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,999.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,808.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,159.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,808.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,808.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $201.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,874.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 11/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327362 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753112 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $425.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 11/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387745 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387747 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387749 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387751 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $368.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $302.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387727 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387729 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387733 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387735 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387713 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387719 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387723 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387737 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369607 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,239.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $313.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,514.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $179.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,769.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $170.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $257.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369828 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 10/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228814277 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 10/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32,708.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387711 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387715 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387717 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387721 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387725 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387739 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $176.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387741 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $88.99 | 09/30/2025 | Non-covered Recipient Entity Illinois Cancer Specialists | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) | No dispute reported | 06/30/2026 | 1235996753 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387689 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387691 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387695 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387697 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 09/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754248 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 09/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942056 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 09/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942102 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228824557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387685 |
| Principal investigator 1 | PFIZER INC. | $66.00 | 08/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228824551 |
| Principal investigator 1 | Amgen Inc. | $50.01 | 08/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | No dispute reported | 06/30/2026 | 1246642495 |
| Principal investigator 1 | Amgen Inc. | $50.01 | 08/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | MyLung Consortium Study (USOR) | No dispute reported | 06/30/2026 | 1246642499 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942068 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174942093 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942125 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942141 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 08/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $21,071.00 | 08/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387687 |
| Principal investigator 1 | PFIZER INC. | $2,250.00 | 07/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228845245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 07/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387683 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753358 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942042 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 07/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369613 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369635 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369663 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369732 |
| Principal investigator 1 | PFIZER INC. | $3,900.00 | 06/16/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228847305 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369667 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369679 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369706 |
| Principal investigator 1 | PFIZER INC. | $1,707.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819177 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819182 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819218 |
| Principal investigator 1 | PFIZER INC. | $1,913.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819225 |
| Principal investigator 1 | PFIZER INC. | $56.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819273 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 06/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 06/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/05/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369687 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/05/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369689 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228854655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369683 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/21/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369722 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,874.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,749.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369677 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 05/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369704 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,100.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185554424 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,750.00 | 04/30/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS NILES | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185554426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369637 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369639 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/29/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/24/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/24/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,416.00 | 04/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387675 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13,421.00 | 04/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387677 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 04/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754224 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $5,200.00 | 04/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387679 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387681 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $420.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PHARMACY | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185554434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369605 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369609 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369675 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369681 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369691 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369695 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,874.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369700 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369728 |
| Principal investigator 1 | Eli Lilly and Company | $349.97 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | Not supplied | No dispute reported | 06/30/2026 | 1187883426 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942080 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 04/15/2025 | Non-covered Recipient Entity Illinois Cancer Specialists-Niles | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942114 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 04/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819233 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369643 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369651 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 04/10/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369611 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387347 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,125.00 | 03/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192140874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369541 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369543 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369545 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369549 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369553 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369595 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,039.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369565 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369567 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369569 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369571 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369573 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 03/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369585 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,200.00 | 03/14/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | No dispute reported | 06/30/2026 | 1185554432 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $368.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $885.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387651 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $211.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $478.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $302.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/12/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369547 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,416.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387643 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $368.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387663 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387667 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369531 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369535 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369539 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369597 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369519 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/20/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369521 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369493 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 02/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,749.00 | 02/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369559 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369593 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387181 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369515 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369523 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369525 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369527 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/10/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369529 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $5,911.20 | 02/07/2025 | Non-covered Recipient Entity Us Oncology Res Llc | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/03/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369505 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753438 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,125.00 | 01/30/2025 | Non-covered Recipient Entity US ONCOLOGY CLINICAL DEVELOPMENT LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192145069 |
| Principal investigator 1 | Amgen Inc. | $12,683.13 | 01/27/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 | No dispute reported | 06/30/2026 | 1246642488 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,700.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185554436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,967.00 | 01/16/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388271 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $408.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PHARMACY | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | No dispute reported | 06/30/2026 | 1185554430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223369479 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369481 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,749.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,749.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369555 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369561 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369563 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369575 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369579 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369581 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,039.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369591 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369601 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369603 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 01/15/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228819268 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/07/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369483 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/07/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369509 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $342,119.29 | 01/03/2025 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369485 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369507 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369511 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/02/2025 | Non-covered Recipient Entity ILLINOIS CANCER SPECIALISTS PC | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223369599 |